This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


trusted source


Engineered DNA 'warhead' targets a common cancer mutation

Engineered DNA 'warhead' targets a common cancer mutation
Graphical abstract. Credit: Science Bulletin (2024). DOI: 10.1016/j.scib.2024.05.017

Tumor protein P53 (TP53) plays an important role in suppressing the growth of tumors. Mutations in the gene for TP53 can have a disastrous effect, hampering the body's ability to fight tumors and even encouraging their growth. Because these are the most common mutations in cancers, TP53 has long been an interesting therapeutic target. However, efforts to destroy the mutant protein have been hampered by the difficulty of finding a way to bind to it.

Now, a team of researchers from Xi'an Jiaotong-Liverpool University (XJTLU) and other research institutes across China have published a study in which they engineered a short sequence of artificial DNA to target a particular mutant version of TP53.

This mutation, called p53-R175H, is linked with lung, colorectal, and breast cancers, and tumors featuring the mutation are more likely to become resistant to chemotherapy treatments, such as cisplatin.

The , dp53m, is a proteolysis-targeting chimera (PROTAC), a type of molecule that consists of two components working together to recognize and degrade a . In dp53m, the first component binds specifically to the mutant p53-R175H protein and does not interact with the non-mutant version of TP53. The second component engages an enzyme called to break down the target mutated protein.

"The magic of PROTACs lies in their ability to recruit enzymes to the target protein, which then starts the process of breaking it down," says Dr. Sijin Wu from the XJTLU Wisdom Lake Academy of Pharmacy.

Engineered DNA 'warhead' targets a common cancer mutation
How PROTACS Use Our Cells' Natural Disposal System to Kill Cancer-Causing Proteins infographic. Credit: National Cancer Institute (NCI), via Wikimedia Commons

Potential treatment

In their paper, published in Science Bulletin, Dr. Wu and co-authors report the results of laboratory tests using dp53m against lung cancer cell cultures and in mice with cancer. The molecule inhibited the growth of cancer cells with the p53-R175H mutation while having no effect on cancer cells with other p53 mutations or with unmutated TP53.

Mice treated with dp53m had much lower levels of than mice given a saline injection as a control. The mice also didn't lose weight, and their other organs were healthy, suggesting that the molecule is not toxic to . The study also found that treatment with dp53m increased the sensitivity of mutant cancer cells to the chemotherapy agent cisplatin.

"The development of dp53m provides strong evidence for the feasibility of using short sequences of RNA or DNA as warheads for PROTACs," Dr. Wu says. "It also could lead to a new potential therapeutic strategy for diseases associated with the p53-R175H mutation."

More information: Lingping Kong et al, An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer, Science Bulletin (2024). DOI: 10.1016/j.scib.2024.05.017

Citation: Engineered DNA 'warhead' targets a common cancer mutation (2024, May 30) retrieved 21 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Research points to an immunotherapy to overcome resistant leukemia


Feedback to editors